Central TrkB blockade attenuates ICV angiotensin II-hypertension and sympathetic nerve activity in male Sprague-Dawley rats

Auton Neurosci. 2017 Jul:205:77-86. doi: 10.1016/j.autneu.2017.05.009. Epub 2017 May 19.

Abstract

Increased sympathetic nerve activity and the activation of the central renin-angiotensin system are commonly associated with cardiovascular disease states such as hypertension and heart failure, yet the precise mechanisms contributing to the long-term maintenance of this sympatho-excitation are incompletely understood. Due to the established physiological role of neurotrophins contributing toward neuroplasticity and neuronal excitability along with recent evidence linking the renin-angiotensin system and brain-derived neurotrophic factor (BDNF) along with its receptor (TrkB), it is likely the two systems interact to promote sympatho-excitation during cardiovascular disease. However, this interaction has not yet been fully demonstrated, in vivo. Thus, we hypothesized that central angiotensin II (Ang II) treatment will evoke a sympatho-excitatory state mediated through the actions of BDNF/TrkB. We infused Ang II (20ng/min) into the right lateral ventricle of male Sprague-Dawley rats for twelve days with or without the TrkB receptor antagonist, ANA-12 (50ng/h). We found that ICV infusion of Ang II increased mean arterial pressure (+40.4mmHg), increased renal sympathetic nerve activity (+19.4% max activity), and induced baroreflex dysfunction relative to vehicle. Co-infusion of ANA-12 attenuated the increase in blood pressure (-20.6mmHg) and prevented the increase in renal sympathetic nerve activity (-22.2% max) and baroreflex dysfunction relative to Ang II alone. Ang II increased thirst and decreased food consumption, and Ang II+ANA-12 augmented the thirst response while attenuating the decrease in food consumption. We conclude that TrkB signaling is a mediator of the long-term blood pressure and sympathetic nerve activity responses to central Ang II activity. These findings demonstrate the involvement of neurotrophins such as BDNF in promoting Ang II-induced autonomic dysfunction and further implicate TrkB signaling in modulating presympathetic autonomic neurons during cardiovascular disease.

Keywords: (3–5): BDNF; Baroreflex; Blood pressure; Neurotrophins.

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Azepines / pharmacology
  • Baroreflex / drug effects
  • Baroreflex / physiology
  • Benzamides / pharmacology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Body Weight
  • Cardiovascular Agents / pharmacology*
  • Defecation / drug effects
  • Defecation / physiology
  • Drinking / drug effects
  • Drinking / physiology
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Hypertension / chemically induced
  • Hypertension / metabolism*
  • Kidney / innervation
  • Male
  • Organ Size
  • Rats, Sprague-Dawley
  • Receptor, trkB / antagonists & inhibitors*
  • Receptor, trkB / metabolism
  • Sympathetic Nervous System / drug effects*
  • Sympathetic Nervous System / metabolism
  • Urination / drug effects
  • Urination / physiology

Substances

  • ANA 12 compound
  • Azepines
  • Benzamides
  • Cardiovascular Agents
  • Angiotensin II
  • Ntrk2 protein, rat
  • Receptor, trkB